• Set up a best-in-industry Gx/biosimilar RI and CI tracking program
• Understand Gx / Biosimilar product development and entry strategies
• This session would focus on the key issues facing the originators / Gx / Biosimilars and their strategies
• How this translates into intelligence options
• What kind of intelligence can be obtained
• This session will be built around real world examples / case studies
This workshop session, will give participants first-hand insights from combined +25 years of experience helping Big Pharma optimize their late-life cycle strategies – i.e. enabling companies to protect and optimize their assets. This interactive session will cover Gx / biosimilar clinical, regulatory, commercial, IP and data exclusivity strategies, the intelligence options available (what, where, why) and actions.
The first part of this session will focus on a model of integration between CI and BS, to create the best value to the decision-making process in the corporation. The second part will be devoted to a comprehensive analysis of a case study that will be presented and discussed in the class through active involvement of the attendees in order to make CI and BS professionals ambassadors of the desired change.
When Pharma and Silicon Valley meet slow and ultra-fast innovation cycles converge. Are our competitive intelligence processes prepared to see “beyond the pill”? This presentation will give you an overview of some of the changes and challenges the pharmaceutical industry will be facing by 2020 and how they may affect how you do your business.
When in the Strategy Making Process is Strategic Intelligence Most Needed and Impactful?
Should CI be Outsourced or Kept In-House?
Which Model is Best? Brand-focused vs TA- focused vs Center of Excellence Models
Does your Company have a Counter-Intelligence System?
Does Insights Enhance or Stifle Innovation?
Having an strong view of competitor activity alone is not enough, it is important to ensure as a BI team we supply not only data but the “so what.”
Using case studies this session will look at how to engage internal customers and ways to successfully add CI to your holistic insights package.
• Most industries have recognized the promise of mobile apps; however some (like pharma) have been slower to adopt, in part due to compliance concerns.
• Relevant apps for the pharma CI community are beginning to gain some ground; we’ll examine the current landscape and discuss the use cases being explored by other vendors.
• Introducing the Larvol App: We’ve worked with our customers to build the first fully integrated pharma mobile app, providing comprehensive coverage that includes clinical and commercial info, disease area pipelines, KOL news, and conference data …and it’s free.
• Competitive Intelligence cycle revisited
• Obstacles that get in the way of “just-right” intelligence
• Getting it “just right” (or at least trying) within your organisation
Companies need to be mindful of certain information and the Antitrust Guidance notes intends to give guidance on how to comply with antitrust law when collecting Competitive Intelligence.
• How to handle competitively sensitive information
• Prohibition on anti-competitive arrangements applies – Article 101 TFEU
• Inter-relationship cartels/information exchange
• Antitrust Guidance on competitive Intelligence
• Recent case laws under Competition Law
• Companies looking to optimise a rare disease portfolio, commonly through partnering, need to consider many factors in addition to the competition including:
• The presentation will discuss some of the key considerations and challenges when supporting companies looking to develop an optimal rare disease portfolio strategy
• Key drivers for integrating CI in MA P&R assessments:
o Unmet need from customers (Patients, Prescribers, Payers, Regulators & Care Givers)
o Potential differentiation criteria
o Commercial viability
• Benefits of integrating CI in MA P&R assessments:
o Better access to planned label by clinical CI
o Better planning for generic launches
o CI with payers and purchases to help product gains access and pricing
• Case study
2. Learn how to work with internal organizational device decision processes to embed competitive insight into the decision process
3. Learn how to better predict your competitors initiatives by better understanding egulatory pathways and device developmental timelines
4. Learn to better understand what has worked and hasn’t worked with regards pharma/device partnerships and how to help your company select the right device partner
5. Learn about tools and techniques available to you to help you stay on top of your competitor device development initiatives
Research shows that this kind of hands-on, minds-on learning produces a deeper, more meaningful understanding of the world and its possibilities. After a brief overview of the methodology and the rationale behind, examples of how it has been used to facilitate workshops aimed at defining a shared vision and guiding principles, or at identifying project risks and counter-strategies within a Pharma company will be presented.
quality of your CI program as well as providing a KPI to your stakeholders the confidence you can bring them when pressure testing their strategy and providing early signals of risks and opportunities in your competitive environment.
Join us for what will be an exciting, hands-on, innovative workshop “outside of the norm” as we simulate a business-critical scenario to test your creativity, adaptability, and of course, challenge your competitive streak!
As part of this workshop you will have the opportunity to:
– Leverage your pharma experience, in a pertinent non-pharma (and entertaining) setting, working in one of many cross-functional teams on a series of time-sensitive business activities
– Experience first-hand, the live development of brand / lifecycle strategy and the various impact factors that can influence response
– Facilitated by agency and industry experts, identify learnings and best-practices that you can take back and implement into your daily practice
The Scenario: You have been summoned into a meeting with your Franchise Team after an intense two weeks compiling a market overview for an area previously unexplored. Interestingly, your Finance & Business Development colleagues are attending today’s meeting and you notice that your General Manager has been copied into the meeting invitation. It appears that something big will be revealed…
Case Study 1 – In-licensing Project
Background: Your company is in the process to in-license a Phase II ready compound in the oncology IO space. The product is an inhibitor and will be second or third to market.
You have been given 8 weeks to prepare a completive assessment for the space and prepare a “pre-diligence” CI report for your managements.
Case Study 2 – In-line CI Project
Background: Your company is a leader in the Diabetes Type II space. Your lead asset is a DPP IV compound and is the key revenue driver for your company. The annual revenue of your compound is $3bn and is planned to grow around 8% Y/Y for the next 3 years.
DPP IV molecules are currently the standard of care approach but a new MOA (SGLT2) is nibbling on your market share. Additionally, the payers in the US put a lot of pressure on pricing / reimbursements. You are currently preparing the annual CI plan and budget for the Global Brand Leader.